Certara, Inc. (CERT)
NASDAQ: CERT · Real-Time Price · USD
8.67
-2.60 (-23.07%)
At close: Nov 7, 2025, 4:00 PM EST
8.77
+0.10 (1.15%)
After-hours: Nov 7, 2025, 7:58 PM EST
Certara Revenue
Certara had revenue of $104.62M in the quarter ending September 30, 2025, with 10.33% growth. This brings the company's revenue in the last twelve months to $415.55M, up 11.47% year-over-year. In the year 2024, Certara had annual revenue of $385.15M with 8.70% growth.
Revenue (ttm)
$415.55M
Revenue Growth
+11.47%
P/S Ratio
3.35
Revenue / Employee
$268,791
Employees
1,546
Market Cap
1.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 385.15M | 30.81M | 8.70% |
| Dec 31, 2023 | 354.34M | 18.69M | 5.57% |
| Dec 31, 2022 | 335.64M | 49.54M | 17.32% |
| Dec 31, 2021 | 286.10M | 42.57M | 17.48% |
| Dec 31, 2020 | 243.53M | 35.02M | 16.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CERT News
- 2 days ago - Certara, Inc. (CERT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Certara Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 days ago - Certara Automates Scientific Workflows with Phoenix® Cloud - GlobeNewsWire
- 9 days ago - Certara to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 9 days ago - Certara Expands Biosimulation Market with AI-Driven QSP Platform - GlobeNewsWire
- 20 days ago - Certara Scientists are Among the Topmost Cited Biopharma Researchers - GlobeNewsWire
- 24 days ago - Why Investors Should Consider Certara Again - Seeking Alpha
- 4 weeks ago - Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025 - GlobeNewsWire